Skip to main content

Advertisement

SpringerLink
Log in

The association between non-Hodgkin lymphoma and methylation of p73

  • Research Article
  • Published:
Tumor Biology

Abstract

To investigate the effects of methylation of the p73 gene on the pathogenesis of non-Hodgkin lymphoma (NHL), the methylation status of the p73 gene promoter and the expression of p73 mRNA were examined in NHLs by methylation-specific polymerase chain reaction (MSP) and reverse transcription-polymerase chain reaction, respectively; p73 protein was detected by Western blotting analysis. Furthermore, the expression of p73 mRNA in NHL cells treated with 5-Aza-2′-deoxycytidine was analyzed. MSP results revealed that the promoter of p73 was methylated in 87.5% of NHLs but was not methylated in reactive hyperplasia lymph node samples. The expression of p73 mRNA was not detected in 83.33% of NHLs but was detected in all of the reactive hyperplasia lymph node samples. The p73 protein was not detected in 91.67% of NHLs but was detected in all of the reactive hyperplasia lymph node samples. The expression of p73 mRNA was detected in NHL cells treated with 5-Aza-2′-deoxycytidine. The inactivation of p73, predominantly by methylation, may be involved in the pathogenesis of NHLs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin’s lymphoma. Oncogene. 2004;23(38):6524–534.

    Google Scholar 

  2. Kok M, Bonfrer JM, Korse CM, de Jong D, Kersten MJ. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin’s lymphoma. Tumor Biol. 2003;24(1):53–60.

    Article  CAS  Google Scholar 

  3. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90(4):809–19.

    Article  PubMed  CAS  Google Scholar 

  4. Dejeux E, Rønneberg JA, Solvang H, Bukholm I, Geisler S, Aas T, Gut IG, Børresen-Dale AL, Lønning PE, Kristensen VN, Tost J. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer. 2010; 9:68.

    Google Scholar 

  5. Natarajan TG, Kallakury BV, Sheehan CE, Bartlett MB, Ganesan N, Preet A, et al. Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon. Cancer Cell Int. 2010;10:13.

    Article  PubMed  Google Scholar 

  6. Yao JY, Zhang L, Zhang X, Ma Y, He ZY, Hui LJ, et al. H3K27 trimethylation is an early epigenetic event of p16INK4a silencing for regaining tumorigenesis in fusion reprogrammed hepatoma cells. J Biol Chem. 2010;285(24):18828–37.

    Article  PubMed  CAS  Google Scholar 

  7. Feinberg AP, Tycko B. Timeline — The history of cancer epigenetics. Nat Rev Cancer. 2004;4(2):143–53.

    Article  PubMed  CAS  Google Scholar 

  8. Siu LLP, Chan JKC, Wong KF, Choy C, Kwong YL. Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas. Br J Haematol. 2003;122(1):70–7.

    Article  PubMed  CAS  Google Scholar 

  9. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, Baylin SB, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt’s lymphoma is associated with 5′ CpG island methylation. Cancer Res. 1999;59(14):3352–6.

    PubMed  CAS  Google Scholar 

  10. Liu M, Taketani T, Li R, Takita J, Taki T, Yang HW, et al. Loss of p73 gene expression in lymphoid leukemia cell lines is associated with hypermethylation. Leuk Res. 2001;25(6):441–7.

    Article  PubMed  CAS  Google Scholar 

  11. Marabese M, Vikhanskaya F, Beoggini M. p73: a chiaroscuro gene in cancer. Eur J Cancer. 2007;43(9):1361–72.

    Article  PubMed  CAS  Google Scholar 

  12. Ramadan S, Terrinoni A, Catani MV, Sayan AE, Knight RA, Mueller M, et al. p73 induces apoptosis by different mechanisms. Biochem Biophys Res Commun. 2005;331(3):713–7.

    Article  PubMed  CAS  Google Scholar 

  13. Kovalev S, Marchenko N, Swendeman S, LaQuaglia M, Moll UM. Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ. 1998;9(11):897–903.

    PubMed  CAS  Google Scholar 

  14. Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee MS, Kantarjian HM, et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res. 2002;8(7):2217–24.

    PubMed  CAS  Google Scholar 

  15. Galm O, Wilop S, Luders C, Jost E, Gehbauer G, Herman JG, et al. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. Ann Hematol. 2005;84 (Suppl 1):39–46.

    Article  PubMed  CAS  Google Scholar 

  16. Roman-Gomez J, Jiminez-Velasco A, Castillejo JA, Agirre X, Barrios M, Navarro G, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood. 2004;104(8):2492–8.

    Article  PubMed  CAS  Google Scholar 

  17. van Doorn R, Zoutman WH, Dijkman R. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol. 2005;23(17):3886–96.

    Google Scholar 

  18. Siu LLP, Chan JKC, Wong KF, Kwong YL. Specific patterns of gene methylation in natural killer cell lymphomas: p73 is consistently involved. Am J Pathol. 2002;160(1):59–66.

    Article  PubMed  CAS  Google Scholar 

  19. Schmelz K, Wagner M, Dörken B, Tamm I. 5-Aza-2′-deoxycytidine induce p21(WAF) express by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer. 2005;114(5):683–95.

    Article  PubMed  CAS  Google Scholar 

  20. Wijermans PW, Lübbert M, Verhoef G, Klimek V, Bosly A. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol. 2005;84(Suppl 1):9–17.

    Article  PubMed  CAS  Google Scholar 

  21. Kantarjian HM, O’Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, et al. Results of decitabine (5-Aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003;98(3):522–8.

    Article  PubMed  CAS  Google Scholar 

  22. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, et al. DNA methylation changes after 5-aza-2 ′-deoxycytidine therapy in patients with leukemia. Cancer Res. 2006;66(10):5495–503.

    Article  PubMed  CAS  Google Scholar 

  23. Link PA, Baer MR, James SR, Jones DA, Karpf AR. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res. 2008;68(22):9358–66.

    Article  PubMed  CAS  Google Scholar 

  24. Roman-Gomez J, Agirre X, Jiménez-Velasco A, Arqueros V, Vilas-Zornoza A, Rodriguez-Otero P, et al. Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol. 2009;27(8):1316–22.

    Article  PubMed  CAS  Google Scholar 

  25. Vilgelm A, El-Rifai W, Zaika A. Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resis Updat. 2008;11(4–5):152–63.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported with the grants from the National Natural Science Foundation of China (no. 81071947, 30770906, and 30270750) and the Science Foundation from the Ministry of Education of China (no. 200805330049).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Molecular Biology Research Center, School of Biological Science and Technology, Central South University, 110 Xiangya Road, Changsha, Hunan, 410078, People’s Republic of China

    Jing-Hong Pei, Sai-Qun Luo, Yan Zhong & Wei-Xin Hu

  2. Tumor Hospital of Hunan Province, 283 Tongzipo Road, Changsha, Hunan, 410013, People’s Republic of China

    Jiang-Hua Chen & Hua-Wu Xiao

  3. Department of Biochemistry, Changzhi Medical College, Changzhi, Shanxi, People’s Republic of China

    Jing-Hong Pei

Authors
  1. Jing-Hong Pei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sai-Qun Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yan Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiang-Hua Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hua-Wu Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei-Xin Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wei-Xin Hu.

Additional information

Jing-Hong Pei and Sai-Qun Luo contributed equally to this publication.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pei, JH., Luo, SQ., Zhong, Y. et al. The association between non-Hodgkin lymphoma and methylation of p73 . Tumor Biol. 32, 1133–1138 (2011). https://doi.org/10.1007/s13277-011-0215-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-011-0215-0

Keywords

Search

Navigation